Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma

Cancer

Volumn 106, Issue 1, 2006, Pages 63-67

  Rozhansky, Flora ^a   Chen, Ming Hui ^b   Cox, Michael C ^c   Dahut, William ^c   Figg, William D ^c   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytostatic therapy; Prostate carcinoma; Prostate specific antigen; Survival

Indexed keywords

CYTOSTATIC AGENT; CYTOTOXIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONE RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CARCINOMA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE II; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 29744466483     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21576     Document Type: Article

References (34)

1. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395-406.
2. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (Stage T2c or lower) prostate cancer. J Urol. 1994;152:1850-1857.
3. Trapasso JG, DeKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994;152:1821-1825.
4. Catalona WJ, Smith DS. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837-1842.
5. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-1642.
6. Berry WR, Laszlo J, Cox E, Walker A, Paulson D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer. 1979;44:763-775.
7. Mulders PFA, Dijkman GA, Fernandez del Moral P, Theeuwes AGM, Debruyne FMJ. Analysis of prognostic factors in disseminated prostatic cancer. Cancer. 1990;65:2758-2761.
8. Eisenberger MA, Crawford ED, Wolf M, et al. Prognostic factors in Stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). Semin Oncol. 1994;21:613-619.
9. Vollmer RT, Kantoff PW, Dawson NA, Vogelzang NJ. A prognostic score for hormone-refractory prostate cancer: analysis of two Cancer and Leukemia Group B studies. Clin Cancer Res. 1999;5:831-837.
10. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. Clin Oncol. 2003;21:1232-1237.
11. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998;160:1220-1229.
12. Tu S-M, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized Phase II trial. Lancet. 2001;357:336-341.
13. Petrylak DP, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
14. Tannock IF, Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
15. Crawford ED, Pauler DK, Tangen CM, et al. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): data from Southwest Oncology Group Study S9916 [abstract 4505]. Proc Am Soc Clin Oncol. 2004;23:382.
16. Dahut WL, Gulley JL, Arlen PM, et al. Randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532-2539.
17. Figg WD, Liu Y, Arlen P, et al. A randomized Phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen-independent prostate cancer and bone metastases. J Urol. 2005;173:790-796.
18. Figg WD, Dahut W, Duray P, et al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;8:1888-1893.
19. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. In: Klein JP, Moeschberger ML, editors. Techniques for censored and truncated data in survival analysis. New York: Springer-Verlag, 1997:229-281.
20. Neter J, Wasserman W, Kutner M, editors. Simultaneous inferences and other topic in regression analysis-1. In: Neter J, Wasserman W, Kutner M, editors. Applied linear regression models, 1st ed. Homewood, II: Richard D. Irwin Inc., 1983:150-153.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Ferro MA, Gillatt D, Symes MO, et al. High dose intravenous estrogen therapy in advanced prostatic carcinoma: use of serum prostate-specific antigen to monitor response. Urology. 1989;134:134-138.
23. Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate-specific antigen as a clinical end point for hormone refractory prostatic cancer. J Urol. 1992;147:931-934.
24. Smith DC, Dunn RL, Stawderman MS, et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 1998;16:1835-1843.
25. Vollmer RT, Dawson NA, Vogelzang NJ. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of Cancer and Leukemia Group B study 9181 of megestrol acetate. Cancer. 1998;83:1989-1994.
26. Scher HI, Kelly WK, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 1999;91:244-251.
27. D'Amico AV, Halabi S, Vogelzang NJ, Small EJ. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: results of a pooled analysis of CALGB HRPC trials. J Clin Oncol. 2004;22(14S):537-556.
28. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431-440.
29. Small EJ, McMillan A, Meyer M, et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol. 2001;19:1304-1311.
30. Emrich LJ, Priore RL, Murphy GP, et al. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res. 1985;45:5173-5179.
31. Sabbatini P, Larson S, Kremer AB, et al. The prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948-957.
32. Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in Phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol. 1994;12:1868-1875.
33. Kelly WK, Scher HI, Mazumdar M, et al. Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol. 1993;11:607-615.
34. Pienta KJ, Redman BG, Bandekar R, et al. A Phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology. 1997;50:401-407.